Simon R. Parker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Simon R. Parker has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Eric O. Ohuma
Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
4 shared publications - Linda Vesel
Ariadne Labs, Harvard T.H. Chan School of Public Health/Brigham and Women's Hospital Boston Massachusetts USA
4 shared publications - Bancy Ngatia
Faculty of Population Health and Epidemiology, London School of Hygiene & Tropical Medicine London UK
3 shared publications - Sara Strout
Faculty of Population Health and Epidemiology, London School of Hygiene & Tropical Medicine London UK
3 shared publications - Amand Floriaan Schmidt
Institute of Cardiovascular Science; University College London; London UK
1 shared publication - Audêncio Victor
School of Public Health, University of Sao Paulo (USP), Sao Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
Discontinuation of antihypertensive and lipid-lowering medication in primary care: a systematic review of observational data and socio-demographic differences
Background: Cardiovascular disease (CVD) risk is chiefly managed pharmacologically in primary care using lipid-lowering therapies (LLTs) and antihypertensives (AHTs), but patients frequently discontinue treatment. Little up-to-date synthesised real-world data for LLT or AHT discontinuation, or how it varies by socio-demographic group, exists. Methods: We systematically reviewed observational studies from PubMed, EMBASE, Web of Science, and CINAHL from 2010-2025 describing discontinuation/restarting prevalence for first-to-third line LLTs/AHTs used for CVD prevention in primary care. Data were extracted on discontinuation/restarting prevalences and associations between discontinuation and sociodemographic factors. Results: Of 5,756 records, 44 (29 LLT; 15 AHT) reports were included. LLT median (IQR) discontinuation and restarting prevalences were 43% (33%-59%) and 58% (40%-61%), respectively. AHT discontinuation and restarting prevalences were 41% (30%-49%) and 28%, respectively. Discontinuation/restarting prevalence depended on discontinuation definition and indication. Patients aged ≈65 years were less likely to discontinue than younger or older patients, for both LLTs and AHTs. In general, women appeared to discontinue LLTs more often than men; men discontinued AHTs more often for primary prevention. Income-based socioeconomic position (SEP) measures were associated with discontinuation, but composite SEP measures were not. Minority ethnic groups were more likely to discontinue LLTs and AHTs. Conclusions: This systematic review of real-world data identified high levels of LLT and AHT discontinuation, and inequalities according to age, sex, and ethnicity. Awareness of these patterns and additional research into patient-level drivers of drug discontinuation could improve health equity by addressing LLT/AHT discontinuation in the highest-risk patients.
Open AccessDiscontinuation of antihypertensive and lipid-lowering medication in primary care: a systematic review of observational data and socio-demographic differences
Background: Cardiovascular disease (CVD) risk is chiefly managed pharmacologically in primary care using lipid-lowering therapies (LLTs) and antihypertensives (AHTs), but patients frequently discontinue treatment. Little up-to-date synthesised real-world data for LLT or AHT discontinuation, or how it varies by socio-demographic group, exists. Methods: We systematically reviewed observational studies from PubMed, EMBASE, Web of Science, and CINAHL from 2010-2025 describing discontinuation/restarting prevalence for first-to-third line LLTs/AHTs used for CVD prevention in primary care. Data were extracted on discontinuation/restarting prevalences and associations between discontinuation and sociodemographic factors. Results: Of 5,756 records, 44 (29 LLT; 15 AHT) reports were included. LLT median (IQR) discontinuation and restarting prevalences were 43% (33%-59%) and 58% (40%-61%), respectively. AHT discontinuation and restarting prevalences were 41% (30%-49%) and 28%, respectively. Discontinuation/restarting prevalence depended on discontinuation definition and indication. Patients aged ≈65 years were less likely to discontinue than younger or older patients, for both LLTs and AHTs. In general, women appeared to discontinue LLTs more often than men; men discontinued AHTs more often for primary prevention. Income-based socioeconomic position (SEP) measures were associated with discontinuation, but composite SEP measures were not. Minority ethnic groups were more likely to discontinue LLTs and AHTs. Conclusions: This systematic review of real-world data identified high levels of LLT and AHT discontinuation, and inequalities according to age, sex, and ethnicity. Awareness of these patterns and additional research into patient-level drivers of drug discontinuation could improve health equity by addressing LLT/AHT discontinuation in the highest-risk patients.
- Open Access
- 18 February 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Implications for Newborn and Child Growth Classification Using INTERGROWTH‐21st and WHO Child Growth Standards
Objective: The aim of this study was to assess how the use of the WHO Child Growth Standards (WHO GS) and the INTERGROWTH‐21st Standards (IG‐21st) affect the classification and interpretation of growth trajectories. Design: A secondary data analysis of an observational cohort study. Setting: Five health facilities participating in the Low Birthweight Infant Feeding Exploration (LIFE) study in Malawi and Tanzania. Population or Sample: 608 moderately low birthweight (1.5 to < 2.5 kg) infants. Methods: Z ‐scores for weight‐for‐age (WAZ), length‐for‐age (LAZ), and head circumference‐for‐age (HCAZ) were calculated at birth using both the WHO GS and the IG‐21st Newborn Size Standard (IG‐21st NBS). Longitudinal trajectories were assessed over three periods (birth–6 months, 6–12 months and 12–24 months) using WHO GS and IG‐21st Preterm Postnatal Standards (IG‐21st PPS). Between 12 and 24 months, all infants were assessed using WHO GS. Conditional growth models were constructed to evaluate deviation from mean growth patterns within GA subgroups. Main Outcome Measures: WAZ, LAZ and HCAZ z ‐scores; prevalence of z ‐scores < −2, and absolute and conditional growth trajectory differences between WHO and IG‐21st standards across three postnatal intervals. Results: At birth, IG‐21st NBS z ‐scores were higher than WHO GS values especially in lower GA subgroups, particularly for LAZ and HCAZ. The proportion of infants with < −2 z ‐scores was substantially lower with IG‐21st PPS than WHO GS in preterm infants for weight (6.1% vs. 95.6%), length (14.4% vs. 89.2%) and head circumference (4.2% vs. 53.5%), respectively. From birth to 6 months, between‐standard z ‐score differences (IG‐21st PPS minus WHO GS) were largest in preterm infants (preterm overall: WAZ: +1.78, LAZ: +1.64, HCAZ: +1.80). From 6 to 12 months, differences persisted but were smaller (preterm overall: WAZ: +0.57, LAZ: +0.79, HCAZ: +0.54), while term infants showed minimal differences between the two standards. Conclusions: The application of the WHO GS alone may misclassify preterm and term infants' growth status, particularly at birth and during early infancy. The use of the IG‐21st standards provides GA‐specific classifications that may more closely align with expected growth patterns in term and preterm infants and could support more accurate monitoring during the first year of life. Based on these implications analyses, we recommend the use of the IG‐21st NBS for cross‐sectional assessment at birth, the IG‐21st PPS from 27 to 64 weeks postmenstrual age, and the WHO GS for all babies thereafter.
- 18 February 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessImplications for Newborn and Child Growth Classification Using INTERGROWTH‐21st and WHO Child Growth Standards
Objective: The aim of this study was to assess how the use of the WHO Child Growth Standards (WHO GS) and the INTERGROWTH‐21st Standards (IG‐21st) affect the classification and interpretation of growth trajectories. Design: A secondary data analysis of an observational cohort study. Setting: Five health facilities participating in the Low Birthweight Infant Feeding Exploration (LIFE) study in Malawi and Tanzania. Population or Sample: 608 moderately low birthweight (1.5 to < 2.5 kg) infants. Methods: Z ‐scores for weight‐for‐age (WAZ), length‐for‐age (LAZ), and head circumference‐for‐age (HCAZ) were calculated at birth using both the WHO GS and the IG‐21st Newborn Size Standard (IG‐21st NBS). Longitudinal trajectories were assessed over three periods (birth–6 months, 6–12 months and 12–24 months) using WHO GS and IG‐21st Preterm Postnatal Standards (IG‐21st PPS). Between 12 and 24 months, all infants were assessed using WHO GS. Conditional growth models were constructed to evaluate deviation from mean growth patterns within GA subgroups. Main Outcome Measures: WAZ, LAZ and HCAZ z ‐scores; prevalence of z ‐scores < −2, and absolute and conditional growth trajectory differences between WHO and IG‐21st standards across three postnatal intervals. Results: At birth, IG‐21st NBS z ‐scores were higher than WHO GS values especially in lower GA subgroups, particularly for LAZ and HCAZ. The proportion of infants with < −2 z ‐scores was substantially lower with IG‐21st PPS than WHO GS in preterm infants for weight (6.1% vs. 95.6%), length (14.4% vs. 89.2%) and head circumference (4.2% vs. 53.5%), respectively. From birth to 6 months, between‐standard z ‐score differences (IG‐21st PPS minus WHO GS) were largest in preterm infants (preterm overall: WAZ: +1.78, LAZ: +1.64, HCAZ: +1.80). From 6 to 12 months, differences persisted but were smaller (preterm overall: WAZ: +0.57, LAZ: +0.79, HCAZ: +0.54), while term infants showed minimal differences between the two standards. Conclusions: The application of the WHO GS alone may misclassify preterm and term infants' growth status, particularly at birth and during early infancy. The use of the IG‐21st standards provides GA‐specific classifications that may more closely align with expected growth patterns in term and preterm infants and could support more accurate monitoring during the first year of life. Based on these implications analyses, we recommend the use of the IG‐21st NBS for cross‐sectional assessment at birth, the IG‐21st PPS from 27 to 64 weeks postmenstrual age, and the WHO GS for all babies thereafter.
- Open Access
- 2 February 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Scenario‐Based Guidance for International Growth Standards ( GIGS ): For Whom, When, and How to Apply the INTERGROWTH ‐21st and WHO Child Growth Standards
Objective: To demonstrate when, for whom, and how to apply the INTERGROWTH−21st (IG‐21st) and WHO Child Growth Standards (WHO GS) using a scenario‐based approach with illustrations utilising a sub‐set of data from a multi‐country low birthweight infant prospective cohort. Design: Scenario‐based methodological study illustrating application of existing international growth standards. Setting: Global; applicable across public health, clinical, research, and epidemiological contexts where child growth monitoring is key. Population or Sample: Neonates and children under 5 years. Methods: Scenario‐based analyses were illustrated using a sub‐set of data from the Low birthweight Infant Feeding Exploration (LIFE) study. Weight‐for‐age z‐scores (WAZ) were computed and compared across two existing international growth standards for illustration. Main Outcome Measures: Differences in infant growth assessment outcomes when applying WHO GS and IG‐21st, including effects of gestational age correction, are demonstrated through WAZ trajectories and classification differences across preterm and term infants. Results: Scenario‐based analyses showed that applying growth standards inappropriately can substantially misclassify infant growth. The GIGS‐recommended approach, using IG‐21st at birth and for preterm growth, and WHO GS for term and later postnatal growth, provides consistent and accurate assessment. Conclusion: The scenario‐based analysis presented in this paper illustrates how growth assessment outcomes can vary depending on the standard used, highlighting the importance of selecting the appropriate growth chart based on gestational age or age at measurement and targeted population. This guidance promotes standardised application of existing international growth standards in research and programmatic settings to facilitate resource allocation and tracking towards global nutrition targets.
- 2 February 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessScenario‐Based Guidance for International Growth Standards ( GIGS ): For Whom, When, and How to Apply the INTERGROWTH ‐21st and WHO Child Growth Standards
Objective: To demonstrate when, for whom, and how to apply the INTERGROWTH−21st (IG‐21st) and WHO Child Growth Standards (WHO GS) using a scenario‐based approach with illustrations utilising a sub‐set of data from a multi‐country low birthweight infant prospective cohort. Design: Scenario‐based methodological study illustrating application of existing international growth standards. Setting: Global; applicable across public health, clinical, research, and epidemiological contexts where child growth monitoring is key. Population or Sample: Neonates and children under 5 years. Methods: Scenario‐based analyses were illustrated using a sub‐set of data from the Low birthweight Infant Feeding Exploration (LIFE) study. Weight‐for‐age z‐scores (WAZ) were computed and compared across two existing international growth standards for illustration. Main Outcome Measures: Differences in infant growth assessment outcomes when applying WHO GS and IG‐21st, including effects of gestational age correction, are demonstrated through WAZ trajectories and classification differences across preterm and term infants. Results: Scenario‐based analyses showed that applying growth standards inappropriately can substantially misclassify infant growth. The GIGS‐recommended approach, using IG‐21st at birth and for preterm growth, and WHO GS for term and later postnatal growth, provides consistent and accurate assessment. Conclusion: The scenario‐based analysis presented in this paper illustrates how growth assessment outcomes can vary depending on the standard used, highlighting the importance of selecting the appropriate growth chart based on gestational age or age at measurement and targeted population. This guidance promotes standardised application of existing international growth standards in research and programmatic settings to facilitate resource allocation and tracking towards global nutrition targets.
- Open Access
- 1 October 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Neonatal and Child Growth Monitoring: A Renewed Call for Uptake and Application of International Growth Standards
Objective: The Guidance for International Growth Standards (GIGS) project aims to improve and promote appropriate application of international growth standards across clinical, research and public health settings.Design: A guidance document providing historical and conceptual context to support the appropriate application of international growth standards.Setting: Global; applicable across public health, clinical, research and epidemiological contexts where child growth monitoring is key.Population or Sample: Neonates and children under 5 years.Methods: Narrative synthesis of key growth monitoring approaches, historical evolution of growth charts and a renewed call for a standardised assessment of child growth using a suite of international standards.Main Outcome Measures: Not applicable. This paper does not report original outcomes, but highlights intended use and application of growth standards.Results: Presents a historical overview of growth chart development, clarifies distinctions between descriptive, prescriptive and customised standards and introduces the rationale and a suite of statistical tools provided by the GIGS project. The paper presents insights from three companion papers, providing a structured guide to growth standard application.Conclusions: The appropriate and correct application of international growth standards offers the opportunity to improve early identification of at‐risk infants and children and reduce global disparities in child health outcomes. The GIGS project provides a structured framework and set of tools to operationalise these standards, supporting consistent application across diverse settings and facilitating progress towards global child health goals.
- 1 October 2025
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Open AccessNeonatal and Child Growth Monitoring: A Renewed Call for Uptake and Application of International Growth Standards
Objective: The Guidance for International Growth Standards (GIGS) project aims to improve and promote appropriate application of international growth standards across clinical, research and public health settings.Design: A guidance document providing historical and conceptual context to support the appropriate application of international growth standards.Setting: Global; applicable across public health, clinical, research and epidemiological contexts where child growth monitoring is key.Population or Sample: Neonates and children under 5 years.Methods: Narrative synthesis of key growth monitoring approaches, historical evolution of growth charts and a renewed call for a standardised assessment of child growth using a suite of international standards.Main Outcome Measures: Not applicable. This paper does not report original outcomes, but highlights intended use and application of growth standards.Results: Presents a historical overview of growth chart development, clarifies distinctions between descriptive, prescriptive and customised standards and introduces the rationale and a suite of statistical tools provided by the GIGS project. The paper presents insights from three companion papers, providing a structured guide to growth standard application.Conclusions: The appropriate and correct application of international growth standards offers the opportunity to improve early identification of at‐risk infants and children and reduce global disparities in child health outcomes. The GIGS project provides a structured framework and set of tools to operationalise these standards, supporting consistent application across diverse settings and facilitating progress towards global child health goals.
- Open Access
- 4 February 2025
- Published by The Open Journal in Journal of Open Source Software
- Vol. 10 (106) , 7655
gigs: A package for standardising fetal, neonatal, and child growth assessment
- 4 February 2025
- Published by The Open Journal in Journal of Open Source Software
- Vol. 10 (106) , 7655
Open Accessgigs: A package for standardising fetal, neonatal, and child growth assessment
- 21 November 2024
- Published by The R Foundation
matchedcc: 'Stata'-Like Matched Case-Control Analysis
- 18 October 2024
- Published by The R Foundation
openFDA: 'openFDA' API